Furthermore, the study provides new information on the dynamics of CDR regulations in wild-type TREM2 and its deleterious variants, and thus, provides clues regarding drug design and TREM2 gene therapy for the treatment of neurodegenerative diseases. This evidence concerns the gene TREM2 and neurodegenerative disease.